구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target.
기전. Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
TROP2
HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer
US, EU, JP
Approved
datroway · datopotamab deruxtecan · Datroway · Dato-DXd · DS-1062 · datopotamab-deruxtecan-dlnk
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
DXd (exatecan derivative, topoisomerase I inhibitor)
Tetrapeptide-based cleavable maleimide linker, DAR ~4
Humanized anti-TROP2 IgG1
Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure.
구조화 데이터
Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure.
TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation.
DXd (exatecan derivative, topoisomerase I inhibitor)
Tetrapeptide-based cleavable maleimide linker, DAR ~4
DAR 4
TROP2 · TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational.
Stomatitis, ocular surface toxicity, and ILD monitoring
Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target.
Pretreated HR+/HER2− metastatic breast cancer; EGFR-mutated NSCLC after TKI
2L+ after endocrine therapy and chemotherapy
IV
6 mg/kg q3w
ORR ~36% in TROPION-Breast01
Stomatitis, ocular surface toxicity, and ILD monitoring
Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target.
Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect.
antibody-dependent cellular cytotoxicity
Topoisomerase I inhibition and DNA double-strand breaks.
TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational.
TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation.
구조화 데이터
xenograft mouse
Human, cynomolgus
ADC ~6 days; released DXd cleared rapidly
PFS by BICR; ctDNA and TROP2 QCS exploratory
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (HR+/HER2− breast cancer)
APPROVAL · 2025년 1월
Accelerated approval in EGFR-mutated NSCLC
APPROVAL
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target.
기전. Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
TROP2
HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer
US, EU, JP
Approved
datroway · datopotamab deruxtecan · Datroway · Dato-DXd · DS-1062 · datopotamab-deruxtecan-dlnk
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
DXd (exatecan derivative, topoisomerase I inhibitor)
Tetrapeptide-based cleavable maleimide linker, DAR ~4
Humanized anti-TROP2 IgG1
Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure.
구조화 데이터
Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure.
TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation.
DXd (exatecan derivative, topoisomerase I inhibitor)
Tetrapeptide-based cleavable maleimide linker, DAR ~4
DAR 4
TROP2 · TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational.
Stomatitis, ocular surface toxicity, and ILD monitoring
Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target.
Pretreated HR+/HER2− metastatic breast cancer; EGFR-mutated NSCLC after TKI
2L+ after endocrine therapy and chemotherapy
IV
6 mg/kg q3w
ORR ~36% in TROPION-Breast01
Stomatitis, ocular surface toxicity, and ILD monitoring
Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target.
Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect.
antibody-dependent cellular cytotoxicity
Topoisomerase I inhibition and DNA double-strand breaks.
TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational.
TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation.
구조화 데이터
xenograft mouse
Human, cynomolgus
ADC ~6 days; released DXd cleared rapidly
PFS by BICR; ctDNA and TROP2 QCS exploratory
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (HR+/HER2− breast cancer)
APPROVAL · 2025년 1월
Accelerated approval in EGFR-mutated NSCLC
APPROVAL
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.